Survivor Views

Share

Three Cancer Survivors

Cancer Survivors’ Views Make a Difference

Survivor Views is a groundbreaking program designed to further engage cancer survivors in the important policy issues that are part of ACS CAN’s fight against cancer.  Over 3,000 cancer survivors have agreed to participate in Survivor Views by responding to regular surveys on policy issues that support the prevention, detection and treatment of cancer and promote survivors’ quality of life.

Through Survivor Views, ACS CAN hears directly from cancer survivors about their experiences and their perspectives on critical cancer-related issues.  This information helps shape the development of policy positions and provides important evidence to support the enactment of these policies.

51%

of cancer patients and survivors have gone into debt to cover the cost of their cancer care.

View the survey findings

Latest Updates

See More Updates

New Survey Finds Nearly 3 in 4 Cancer Patients and Survivors who Rely on the Marketplace for Comprehensive Coverage Risk Losing Access to Lifesaving Care if the Enhanced Premium Tax Credits are not Extended

December 2, 2025
National

The American Cancer Society Cancer Action Network (ACS CAN) today released results from a survey exploring the impact of the enhanced premium tax credits on cancer patients and survivors who rely on the Marketplace for comprehensive health insurance coverage.

Millions of North Carolinians’ Medical Debt Erased

October 14, 2025
North Carolina

RALEIGH, N.C. - More than 2.5 million North Carolinians had over $6.5 billion in medical debt relieved this week, fulfilling the promise of the state’s plan to engage hospitals in a program to relieve medical debt and institute policies to prevent patients from incurring additional debt. By participating,

New Study Underscores Importance of Pharmacogenomic Testing to Patients and Finds Many Aren’t Aware of the Benefits

August 14, 2025
National

A new ACS CAN study released in the Journal of the American Medical Association (JAMA) finds many patients aren’t made aware of the importance of pharmacogenomic (PGx) testing. A form of biomarker testing, PGx testing examines how variations in a patient’s inherited genes may impact how they respond to different drugs and can improve the effectiveness of treatment and reduce the risk of adverse drug reactions.

Survey Finds Almost One-third of Adults Have Been More Than One Year Behind on Cancer Screenings

May 14, 2025
National

A new survey by the American Cancer Society Cancer Action Network (ACS CAN) found that 31% of adults have been more than one year behind on cancer screenings.

Survivor Views Resources

Survivor Views on Health Care Tax Credits

December 2, 2025

Our latest Survivor Views survey finds nearly three in four cancer patients and survivors who rely on the marketplace for comprehensive coverage stand to lose access to lifesaving care if the enhanced premium tax credits are not extended. Additionally, one quarter of those who rely on the enhanced health care tax credits report that if the credits expire, they will become uninsured or forced into a non-comprehensive "junk" plan.

Survivor Views on Artificial Intelligence and FDA Medical Product Reviews

September 14, 2025

Our latest survey finds 80% of cancer patients and survivors agree that industries making FDA-regulated products should provide some of the cost of FDA’s public health oversight. The survey also reveals hesitency toward the increased use of AI, mirroring the sentiment of the American public. Cancer patients and survivors offer tempered support for the use of AI in FDA product reviews if funding cuts extend review times, with a plurality undecided on whether they support or oppose it.

National Screening Survey

May 14, 2025

Our latest survey finds that 31% of screening-age adults have been more than one year behind on recommended routine cancer screenings. Over half say out-of-pocket costs are a barrier to getting screened, while 47% report that getting insurance approvals for covered screenings is a barrier.

Choice in Treatment Modality Overwhelmingly Important to Cancer Patients & Survivors

February 18, 2025

Nearly all (94%) cancer patients and survivors agree that it is important for patients and their providers to have the ability to choose the type of treatment and delivery that best suits their needs. Patients who have taken oral anti-cancer drugs rate their experience significantly better compared to experiences with IV infusions on several metrics including coping with side effects, time spent in provider visits, and quality of life.

Cancer Patients & Survivors Strongly Support Maintaining Funding for Medicaid and Protections for Preexisting Conditions

February 12, 2025

Our latest Survivor Views survey finds that across party lines cancer patients and survivors oppose reducing funding for Medicaid (73%), and fewer than one-in-five support adding a work requirement for Medicaid (19%). The survey also finds overwhelming support for protecting coverage for those with preexisting conditions (81%), and explores questions related to allowing non-ACA plans in the marketplace, which a majority (65%) feel would be confusing.

Survivor Views on Enhanced Premium Tax Credits

January 28, 2025

Our latest survey finds that 86% of those receiving enhanced premium tax credits would have difficulty getting care if the credits expire at the end of 2025, and very few (25%) are aware of the enhanced credits expiring.




Survivor Views is supported by Amgen, Cell Centric, BMS, Organon, Merck, and Novartis